Post-operative diagnostic revision for Crohn Disease after subtotal colectomy for inflammatory bowel disease.

Title: Diagnostic revision after sub-total colectomy

Hélène Hermand, Jérémie Lefèvre, Conor Shields, Najim Chafai, Clotilde Debove, Laurent Beaugerie, Magali Svrcek, Yann Parc

► To cite this version:

Hélène Hermand, Jérémie Lefèvre, Conor Shields, Najim Chafai, Clotilde Debove, et al.. Post-operative diagnostic revision for Crohn Disease after subtotal colectomy for inflammatory bowel disease. Title: Diagnostic revision after sub-total colectomy. International Journal of Colorectal Disease, 2020, 10.1007/s00384-020-03783-9 . hal-02996378

HAL Id: hal-02996378

<https://hal.sorbonne-universite.fr/hal-02996378>

Submitted on 9 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Original Research Article

Post-operative diagnostic revision for Crohn Disease after subtotal colectomy for inflammatory bowel disease.

Hélène Hermand, (MD)¹, Jérémie H. Lefèvre, (MD, PhD)¹, Conor Shields, (MD)², Najim Chafai, (MD)¹, Clotilde Debove (MD)¹, Laurent Beaugerie, (MD)³, Magali Svrcek, (MD, PhD)³, Yann Parc, (MD, PhD)¹, for the Saint-Antoine IBD Network.

¹Sorbonne Université, Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France.

²Mater Misericordiae University Hospital, Dublin, Ireland.

³Sorbonne Université, Department of Pathology, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France.

⁴Sorbonne Université, Department of Gastroenterology, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France.

Short Title: Diagnostic revision after sub-total colectomy

Corresponding author:

Prof. Jérémie LEFEVRE, Department of Digestive Surgery, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France.

Tel: +33 1 49 28 25 47

Fax: +33 1 49 28 25 48

E-mail: jeremie.lefevre@aphp.fr

Twitter: @jeremielefevre

Orcid: <https://orcid.org/0000-0001-7601-7464>

Number of Tables: 2

Number of figures: 2

Word count: 2662

Keywords: colitis; subtotal colectomy; Crohn's colitis; ulcerative colitis

Abstract:

Purpose: Subtotal colectomy (STC) is performed for severe acute and refractory colitis. The diagnosis can be difficult even after the surgery when colectomy specimen has overlapping features of Ulcerative Colitis (UC) and Crohn's disease (CD). The aim of this study was to evaluate the rate of post-operative diagnostic revision to CD after surgery and determine predictors factors.

Methods: Retrospective study of 110 patients who underwent STC (2005-2018).

Results: pre-operative diagnosis comprised: UC=80(73%), CD=11(10%) and Unclassified Colitis (IBDU=19, 17%). Initial diagnosis of IBDU and UC was modified to CD in 6 patients (6 %) after STC. The final diagnosis after the follow-up of 10 ± 6 years switched from CD for 8 patients (9%). The multivariate analysis showed that patients with a colitis evolving for less than 10 years and initial diagnosis of IBDU were the two independent factors associated with an increased risk of diagnosis change to CD ($p=0.03$; $p=0.016$). At the end of the follow up 15 patients (14%) had a definitive stoma.

Conclusions: In patients with IBD, attention must be paid to determine the right restorative strategy to patients with an evolution of the disease less than 10 years or with IBDU who are more at risk to have a diagnosis change to CD after STC.

INTRODUCTION:

The spectrum of inflammatory bowel disease (IBD) encompasses both Crohn's disease (CD) and ulcerative colitis (UC). While UC affects solely the rectum and the colon, CD may be found throughout the gastrointestinal tract, including the rectum and colon in the case of CD.[1-5] In some cases, patients with chronic colitis clearly have IBD based on the clinical history but macroscopy and/or endoscopic biopsies show no definitive features of UC or CD; the term unclassified colitis (IBDU) is thus used for these patients. [6] Post-operative examinations of resections of such cases usually provide definitive evidence of UC or CD. The diagnosis can be difficult even after the surgery when colectomy specimen has overlapping features of UC and CD and, in those cases, pathologists use the term of Indeterminate Colitis (IC).

Accurately distinguishing between UC and CD is crucial as the surgical treatment for each differs considerably. While restorative proctocolectomy (RPC) is the usual approach in cases of UC[7-9], many surgeons are reticent to offer it to patients with CD.[10, 11] Indeed, pouch failure is frequently accompanied by an alteration of the original diagnosis from UC to CD.[12, 13] Therefore, strategies to minimise the need for post-operative revision of the diagnosis are critical.

There is a variety of indications for surgery in patients with colitis. The detection of dysplasia while the patient is under surveillance is observed most frequently in the setting of multiple biopsies, and prompts RPC.[14] However, surgery is also indicated in at least two other situations in which a long history and multiple biopsies are not always available: severe acute colitis and refractory colitis. These two situations now account for the majority of the indications for surgery.[15, 16] It is more likely that it in such cases diagnosis uncertainty is more frequent, resulting in increased rates of pouch failure after RPC.

1 The aim of this study was to evaluate the rate of diagnosis change and to identify predictors
2 factors of diagnosis revision to CD for patients who underwent STC for severe acute colitis or
3 refractory colitis.
4
5
6
7
8

9 **METHODS AND PATIENTS:**

10 This retrospective observational study reports a monocentric experience in the management of
11 IBD requiring surgical treatment in an expert center for IBD, Saint Antoine Hospital in Paris.
12
13 All patients who underwent STC at St Antoine's hospital between 2005 and April 2018 were
14 included.
15
16
17
18
19
20

21 The diagnosis of colitis was based on a combination of clinical features, imaging modalities
22 endoscopic findings, and histological interpretation of biopsies by pathologists expert in gastro
23 intestinal pathology including IBD.
24
25
26
27

28 Severity of the colitis was evaluated with the Lichtiger's score.[17] Complicating factors
29 including colectasia or colonic perforation were derived from CT scans and endoscopy was
30 performed when clinically indicated. There is two frequent indications for STC in patients with
31 IBD: first patients with severe acute colitis defined according to Truelove and Witts' criteria or
32 a Lichtiger's score higher than 10 who were admitted acutely and who failed to respond to
33 maximum medical treatment or who had developed complications as a result of their pathology
34 (mostly sepsis, colectasia or haemorrhage), and required emergency surgical intervention. The
35 second indication is for patients with refractory colitis defined as steroid-dependent colitis
36 (inability to reduce steroids below the equivalent of prednisolone 10mg/day within 3 months or
37 relapse within 3 months of stopping steroids) or steroid-refractory colitis (active IBD despite
38 prednisolone up to 0.75 mg/kg/day for 4 weeks) or immunomodulatory-refractory colitis (active
39 IBD despite thiopurines or mercaptopurine for 3 months).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

STC was performed by laparoscopy or laparotomy.[18] Ileostomy was always created in the right iliac fossa. Sigmoidostomy was created either suprapubic in the midline incision or with the ileostomy depending on surgeon's choice.

After STC patients were reclassified as CD, UC, or IC either after pathological analysis, or either during the follow up according to the guidelines proposed by the European Society of Pathology and the European Crohn's and Colitis Organization.[6, 19] Pathological diagnosis of IC on resected specimens relied on the presence of clear evidence of IBD, with "overlapping features" or the absence of a "clear diagnostic pattern", with insufficient criteria to make a definite diagnosis of UC or CD.[6] Before STC some patients were considered to have an unclassified colitis (IBDU) as the diagnosis was only made on disease history and endoscopic findings. For these patients, no histology was available before STC. A decision to attempt restore intestinal continuity was made only after definitive pathology results were available.

Statistical analysis

Descriptive analyses are presented as median (range) or mean $\pm$ standard deviation for quantitative data and as number of patients (percentage of patients) for categorical data. The correlation between diagnostic modification and initial diagnosis was studied by univariate analysis (chi-squared). All tests were two-sided, and a p value <0.05 was considered to be significant. The multivariate analysis was performed using a backward stepwise logistic regression model that included all variables with a p value <0.1 in univariate analysis.

RESULTS:

Patients:

One hundred and ten patients (mean age of 69 ± 23 years) underwent STC for colitis. The mean time between the diagnosis of IBD and surgery was 10 ± 6 years. Details of the patients can be

found in Table 1. STC was performed for severe acute colitis in 58 patients (53%), of whom 23 (40%) exhibited an acute complication related to their disease and for refractory colitis in the remaining 52 patients (47%). 61 (55%) patients had received corticosteroid treatment within 6 months of surgery, 69 (63%) had immunosuppressive therapy within 6 months, while 67 (61%) had been treated with monoclonal TNF α inhibitors.

Diagnosis revision (Figure 1):

The pre-operative diagnosis comprised UC (n=80, 73%), CD (n=11, 10%), and IBDU (n=19, 17%). The pathological analysis of the piece of STC allowed a rectification of the initial diagnosis for several patients. The previously IBDU cases (n=19, 17%) were reclassified mainly as UC (n=14, 74%), as CD (n=4, 21%) and IC (n=1, 5%). Among the patients initially diagnosed as UC (n=80, 73 %), 6 patients (8 %) had a change of diagnosis: 4 (5%) became IC and 2 (3%) CD. There was no change of diagnosis for patients initially diagnosed with CD.

Diagnosis modifications continued during the follow-up period of 10 years (± 5 years), during which patients had their surgery to restore intestinal continuity.

Among the 80 patients initially diagnosed with UC, 69 (86%) didn't have a change of diagnosis at the end of the follow-up. Among the 19 patients initially diagnosed with IBDU only 1 patient stayed with an IC.

During the follow-up, 8 patients (9%) among those with UC and IC were deemed to have CD.

At the end, compared to the initial diagnosis, 14 patients (14%) classified UC, IBDU or IC were found to be CD.

We performed an univariate analysis between the group of patients diagnosed with UC, IBDU or IC with a change of diagnosis to CD during the study and the patient who stayed with the initial diagnosis to determine predictors factors to be reclassified as CD. (Table 2) Patients with

1 a colitis evolving for more than 10 years had less risk to have a change of diagnosis to CD,
2 p=0.035. Patients with an initial diagnosis of IBDU were more likely to have a change of
3 diagnosis to CD, OR= 4.08 IC 95% [0.9937; 16.1628] p=0.026. In multivariate analysis those
4 two criterias were also associated with an increased risk of diagnosis change to CD with
5 respectively p=0.03 and p=0.016 with an OR=5.81 [1.62-18.54] for IBDU patients.
6
7
8
9
10

11 *Impact of diagnostic revision in the strategy of restoration of intestinal continuity:*

12 The restorative continuity strategy was mainly guided by the pathological analysis of the STC
13 specimen but also by risks factors of poor functional result as age, anal incontinence and severe
14 perineal lesions. (Figure 2)
15

16 Excluding patients who were lost to follow up (n=2) or who died during the study (n=2), at the
17 end of the follow up of 10 years (± 5 years), 15 patients (14%) had a definitive stoma.
18

19 Among the 11 patients with an initial diagnosis of CD, 3 (27%) had a definitive stoma
20 including 2 who never had an attempt to restore continuity according to their will.
21

22 Among the 14 patients with a diagnosis change to CD, 2 (14%) had a definitive stoma at the
23 end of the follow up and 3 patients had a temporary ileostomy more than one year for the
24 management of their CD. There was no difference of rate of definitive stoma between those
25 two groups, p=0.623.
26

27 Among the 72 patients with a UC from the beginning, 7 patients (10%) had a definitive stoma.
28 Retrospectively, all histological samples of patients deemed to have CD were reanalysed to
29 determine if features of CD existed. Details of those patients are given in supplementary table
30 1.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **DISCUSSION:**

53
54
55
56
57
58
59
60
61
62
63
64
65

1 Diagnostic revision after surgical treatment of UC is a quagmire for physicians. Many patients
2 seek a RPC with the hope that they may be rendered stoma free. However, a resurgence of
3
4 symptoms may prompt a reclassification of the diagnosis. The ileal pouch and the perineum are
5
6 the most frequent sites of disease, which can lead to the construction of a diverting stoma which
7
8 may become a permanent fixture. If the diagnosis had been accurate initially, the patient may
9
10 have been spared restorative surgery, with the associated risks and dashed hopes. Even if one
11
12 argues that an ileal pouch in the setting of CD may be appropriate in some cases, prior
13
14 knowledge of the presence of CD would alter post-operative management and would colour
15
16 both patient and clinician expectations.
17
18
19
20

21 Indications for surgery in UC can be divided into four categories: functional, prophylactic for
22
23 cancer, resistance to treatment, and acute complications. Surgery for functional reasons and
24
25 cancer prevention is most commonly seen in the context of a long disease history. In these
26
27 cases, uncertainty over the diagnosis is unlikely. On the contrary, in the case of treatment
28
29 resistance and especially in case of acute colitis and acute severe complications, the disease
30
31 history may be short, with a corresponding increased risk of diagnostic revision after surgery.
32
33
34 In the present series, the delay between initial diagnosis and STC was only 6.5 years, which is
35
36 quite short for a chronic disease. The aims of this study were then to evaluate the diagnostic
37
38 revision rate to CD after pathologic examination of the specimen obtained after STC and the
39
40 one observed after surgery to restore intestinal continuity and during the follow up with
41
42 endoscopic biopsies.
43
44
45
46
47

48 In our series, before surgery 19 patients were considered to have IBDU. This must be regarded
49
50 as a different entity to IC. An unclassified designation may result from a lack of material for
51
52 pathological examination. In the absence of specific features of CD, a definitive diagnosis may
53
54 prove elusive. If these patients had been deemed to have IC, and underwent subsequent RPC, 4
55
56 patients with CD, and one with an IC would have undergone pouch surgery. It can be argued
57
58
59
60
61
62
63
64
65

that in the present series, 2 patients (14%) among the 14 who were considered to have UC after STC, while previously unclassified, ultimately were found to have CD. Same results are found in the literature as Zaghiyan and al.[20] However, when comparing diagnostic revision rates between patients who had UC either after being considered to have one or an unclassified one, there was no difference. Moreover, the long-term diagnostic modification rate in these two situations is within the ranges reported in the literature. In fact, the risk of diagnostic modification was significantly higher among patients who had their initial diagnosis modified and especially among those who had their diagnosis modified from UC to IC. In this specific group of patients, the rate of secondary diagnostic modification reached 25%. Such a rate is higher than the one observed in cases of IC in the literature.[21-26] With this finding in mind, should these patients have had an operation other than restorative proctocolectomy? Probably not, as ileorectal anastomosis in CD is not always accompanied by a good result, and RPC is offered to only highly selected patients. Thus, those patients with a modified diagnosis of IC, after previously being classed as UC, are more likely to fulfil the criteria of a CD patient who would be considered for RPC.[11, 12] In the present series, one patient with CD underwent RPC without disease recurrence at the last follow up.

The term IC is used to describe colitis without a clear argument for UC or CD after colectomy, in our series the frequency was 5% just after STC and 4% after follow-up. These rates are rather low compared to those found in the literature between 3% and 10%. [27] In our series, patients reclassified during the follow-up were patients with CD. In our study 14 patients (13%) classified UC, IBDU or IC were found to be CD after pathological examination of the piece of resections or during the follow up with the occurrence of perineal lesions or ileo-vaginal fistula. Seven of them (50%) had a restorative proctectomy and 4 (43%) developed severe complications of the ileal pouch which required a diverting stoma for several years. These complications highlight the importance of a good classification of the IBD in the strategy of restorative

continuity as shown in the study of Netz et al, the long-term quality of life for these patients is lower than in case of IRA. Taking into account the clinical impact, we analyzed individually the characteristics of the patients whose diagnosis was finally changed for CD: few studies have analyzed precisely the histological data of these patients, the Japanese study of Matsui et al. analyzed these features in their series of 735 patients with IBD with 23 patients whose diagnosis was modified (3%): patients initially UC whose diagnosis was rectified during follow-up for CD (n=8, 10%) have been done only after the detection of granulomas on biopsy material, the initial diagnosis of UC was based mainly on the diffuse appearance of colitis and the lack of cobblestones. In our series we have rectified the diagnosis of CD rather on a panel of histological arguments rather than on the exclusive presence of granulomas according to a methodology closer to the study of Henriksen and al. whose results are comparable to ours.[28]

The univariate analysis realized, confirmed by an multivariate analysis to determine predictive factors of modification of the diagnosis found that disease evolution duration of less than 10 years and the diagnosis of IBDU were associated with an increased risk of modification of the diagnosis toward CD. This result enlightning the fact that for patients with a recent onset of the colitis, it might be necessary to take time to choose the right reconstruction strategy.

The confirmation of the original diagnosis by pathologic examination of the specimen obtained at STC allows the choice of subsequent appropriate surgeries, while particular heed needs to be paid to patients who have had a diagnosis of UC modified to IC after STC.

Statements

List of collaborators of the Saint Antoine IBD Network: Lionel Arrivé, Laurent Beaugerie, Anne Bourrier, Marine Camus, Najim Chafai, Edouard Chambenois, Ulriikka Chaput, Clotilde Debove, Charlotte Delattre, Xavier Dray, Jean-François Fléjou, Guillaume Le Gall, Nadia Hoyeau, Julien Kirchgesner, Cécilia Landman, Jérémie H. Lefèvre, Philippe Marteau, Chloé Martineau, Laurence Monnier-Cholley, Isabelle Nion-Larmurier, Violaine Ozenne, Yann Parc, Philippe Seksik, Harry Sokol, Magali Svrcek, Emmanuel Tired.

Declarations

Funding source: No funding

Disclosure statement: the authors have no conflict of interest to declare

Availability of data and material: on request to the corresponding author

Acknowledgement: None

Statement of ethics: No ethical approval was needed as it was a retrospective study. All patients had given a written informed consent.

Author contribution:

- Study conception: JHL, LB, YP
- Data acquisition: HH, MS, NC
- Analysis of data: HH, JHL, MS, NC
- First draft writing: HH, JHL, CS, MS, LB, YP
- Manuscript correction: All authors
- Final approval: All authors

REFERENCES:

1. Kalla R, Ventham NT, Satsangi J, Arnott ID. Crohn's disease. *BMJ* 2014; **349**: g6670.
2. Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. *BMJ* 2013; **346**: f432.
3. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'. *J Clin Pathol* 1978; **31**: 567-77.
4. Lee KS, Medline A, Shockey S. Indeterminate colitis in the spectrum of inflammatory bowel disease. *Arch Pathol Lab Med* 1979; **103**: 173-6.
5. Wells AD, McMillan I, Price AB, Ritchie JK, Nicholls RJ. Natural history of indeterminate colitis. *Br J Surg* 1991; **78**: 179-81.
6. Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 827-51.

- 1
2
3
4
5
6
7. Pemberton JH, Kelly KA, Beart RW, Jr., Dozois RR, Wolff BG, Ilstrup DM. Ileal
pouch-anal anastomosis for chronic ulcerative colitis. Long-term results. *Ann Surg*
1987; **206**: 504-13.
- 8
9
10
11
12
13
14
15
16
17
18
8. Brunel M, Penna C, Tiret E, Balladur P, Parc R. Restorative proctocolectomy for distal
ulcerative colitis. *Gut* 1999; **45**: 542-5.
- 19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
9. Goudet P, Dozois RR, Kelly KA, Melton LJ, 3rd, Ilstrup DM, Phillips SF. Changing
referral patterns for surgical treatment of ulcerative colitis. *Mayo Clin Proc* 1996; **71**:
743-7.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
10. Turina M, Remzi FH. The J-pouch for patients with Crohn's disease and indeterminate
colitis: (when) is it an option? *J Gastrointest Surg* 2014; **18**: 1343-4.
11. Panis Y, Poupard B, Nemeth J, Lavergne A, Hautefeuille P, Valleur P. Ileal pouch/anal
anastomosis for Crohn's disease. *Lancet* 1996; **347**: 854-7.
12. Hartley JE, Fazio VW, Remzi FH, Lavery IC, Church JM, Strong SA, et al. Analysis of
the outcome of ileal pouch-anal anastomosis in patients with Crohn's disease. *Dis Colon*
Rectum 2004; **47**: 1808-15.
13. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in
patients with Crohn's disease. *Dis Colon Rectum* 1996; **39**: 893-8.
14. Peyrin-Biroulet L, Bonnaud G, Bourreille A, Chevaux JB, Faure P, Filippi J, et al.
Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee
of the French Society of Digestive Endoscopy (SFED). *Endoscopy* 2013; **45**: 936-43.
15. Katz JA. Medical and surgical management of severe colitis. *Semin Gastrointest Dis*
2000; **11**: 18-32.
16. Truelove SC. Medical management of ulcerative colitis and indications for colectomy.
World J Surg 1988; **12**: 142-7.

17. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. *Lancet* 1990; **336**: 16-9.
18. Hor T, Lefevre JH, Shields C, Chafai N, Tired E, Parc Y. Female sexual function and fertility after ileal pouch-anal anastomosis. *Int J Colorectal Dis* 2016; **31**: 593-601.
19. Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V, et al. The histopathological approach to inflammatory bowel disease: a practice guide. *Virchows Arch* 2014; **464**: 511-27.
20. Zaghiyan K, Kaminski JP, Barmparas G, Fleshner P. De novo Crohn's Disease after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis and Inflammatory Bowel Disease Unclassified: Long-Term Follow-Up of a Prospective Inflammatory Bowel Disease Registry. *Am Surg* 2016; **82**: 977-81.
21. Stewenius, Adnerhill I, Ekelund GR, Floren CH, Fork FT, Janzon L, et al. Operations in unselected patients with ulcerative colitis and indeterminate colitis. A long-term follow-up study. *Eur J Surg* 1996; **162**: 131-7.
22. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. *Gut* 1997; **40**: 328-32.
23. McIntyre PB, Pemberton JH, Wolff BG, Dozois RR, Beart RW, Jr. Indeterminate colitis. Long-term outcome in patients after ileal pouch-anal anastomosis. *Dis Colon Rectum* 1995; **38**: 51-4.
24. Kangas E, Matikainen M, Mattila J. Is "indeterminate colitis" Crohn's disease in the long-term follow-up? *Int Surg* 1994; **79**: 120-3.
25. Pezim ME, Pemberton JH, Beart RW, Jr., Wolff BG, Dozois RR, Nivatvongs S, et al. Outcome of "indeterminant" colitis following ileal pouch-anal anastomosis. *Dis Colon Rectum* 1989; **32**: 653-8.

26. Koltun WA, Schoetz DJ, Jr., Roberts PL, Murray JJ, Collier JA, Veidenheimer MC. Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis. *Dis Colon Rectum* 1991; **34**: 857-60.
27. Matsui T, Yao T, Sakurai T, Yao K, Hirai F, Mataka H, et al. Clinical features and pattern of indeterminate colitis: Crohn's disease with ulcerative colitis-like clinical presentation. *J Gastroenterol* 2003; **38**: 647-55.
28. Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). *Scand J Gastroenterol* 2006; **41**: 1037-43.

Figure legends

Figure 1. Evolution of the diagnosis.

STC: Subtotal Colectomy

Figure 2. Digestive continuity strategy after STC.

STC: subtotal colectomy; IBD inflammatory Bowel Disease; IBDU inflammatory Bowel Disease Unclassified; CD: Crohn's disease; UC: ulcerative colitis; RPC: Restorative Proctocolectomy; IRA: ileorectal anastomosis; DS: Definitive Stoma; TS: Temporary Stoma; LTFU: Lost To Follow Up; APR: Abdomino-Perineal Resection

Table 1. Patients' characteristics before STC and indication for surgery

Characteristics	N (%) or Average $\pm$ SD
Women	44 (40%)
Age(y)	69 $\pm$ 23
BMI (Kg/m ²)	20 $\pm$ 2
Active Smoker	21 (19%)
ASA score	
2	85 (77%)
3	17 (15%)
4	2 (4%)
Age at diagnosis of IBD (y)	57 $\pm$ 15
Time between diagnosis and STC (y)	5 $\pm$ 3
Preoperative diagnosis	
Crohn's disease	11 (10%)
Ileitis	5 (46%)
Anoperineal lesion	8 (73%)
Ulcerative colitis	80 (73%)
Back wash ileitis	3 (4%)
Unclassified colitis	19 (17%)
Indications for surgery	
Emergency	58 (53%)
Severe acute colitis	35 (60%)
Toxic Dilatation	7 (12%)
Sepsis	11 (19%)
Haemorrhage	5 (9%)
Refractory colitis	52 (47%)
With dysplasia	7 (13%)
Lichtiger's score	
≤ 8	21 (19%)
8<lichtiger ≤ 10	16 (15%)
10<lichtiger ≤ 12	27 (25%)
>12	46 (42%)
Treatment at time of surgery	
Steroid prescription	100 (91%)
≤ 6 months	61 (61%)
6 months $\leq \leq 1$ year	12 (12%)
≥ 1 year	21 (21%)
Dose of steroids (PO prednisone equivalence in mg) at time of surgery	40 $\pm$ 14
Intravenous steroid before surgery	45 (41%)
Immunosuppressive therapy within 6 months	69 (63%)
TNF inhibitors within 6 months	67 (61%)

Table 2. Univariate analysis of demographics and pre-operative characteristics of patients with initial diagnosis of UC or IC with a change of diagnosis for CD compared to patients who stayed UC or IBDU.

Characteristics	Patients UC or IC without change of diagnosis n= 85	Patients with a change of diagnosis to CD n= 14	Univariate analysis p=	Multivariate analysis p=
Age<40 years at the time of STC	49 (58%)	11 (79%)	0.237	
Male gender	50 (59%)	7 (50%)	0.571	
BMI $\geq$ 30	2 (2%)	1 (7%)	0.319	
Active Smoker	16 (19%)	3 (21%)	1	
ASA score $\geq$ 3	15 (18%)	1 (7%)	0.246	
Age at the time of diagnosis > 20y	66 (78%)	8 (57%)	0.18	
Time between diagnosis and STC $\leq$ 10y	62 (73%)	14 (100%)	0.035	0.003
Preoperative diagnosis				
UC	72 (85%)	8 (57%)		
IBDU	13 (15%)	6 (43%)	0.026	0.016
Indications for surgery				
Emergency	43 (51%)	10 (71%)		
Refractory colitis	42 (49%)	4 (29%)	0.247	
Treatment at time of surgery				
Use of steroids within 6 months	53 (62%)	7 (50%)	0.393	
TNF inhibitors	52 (61%)	7 (50%)	0.558